Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 7Phase 1/2 2

Status

Completed 11Active not recruiting 6Recruiting 5Not yet recruiting 3Withdrawn 2Terminated 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 1Melanoma 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × trametinib × Clear all
NCT02143050 2023-11-18

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

University of Louisville

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡